Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN).

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Oncology

• Publication date

  2004-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2004.22.14_SUPPL.5541PMID 28013997
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)

  2011cites this paper
• Tumores del área ORL. Tratamiento de quimiorradioterapia

  2007cites this paper
• Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

  2007cites this paper
• The role of taxanes and targeted therapies in locally advanced head and neck cancer

  2007cites this paper
• Targeted therapies in head and neck cancer

  2007cites this paper
• Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?

  2007cites this paper
• Targeting the ErbB family in head and neck cancer

  2007cites this paper
• Cetuximab in the treatment of head and neck cancer

  2006cites this paper
• Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer.

  2006cites this paper
• Promising new advances in head and neck radiotherapy.

  2005cites this paper
• Current treatments and promising investigations in a multidisciplinary setting.

  2005cites this paper
• The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies.

  2005cites this paper